Somewhat Positive Press Coverage Somewhat Unlikely to Impact Biopharmx Corp (NASDAQ:BPMX) Share Price
News articles about Biopharmx Corp (NASDAQ:BPMX) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Biopharmx Corp earned a news impact score of 0.11 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.9914187060953 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of Biopharmx Corp (NASDAQ BPMX) opened at 0.292 on Tuesday. The company’s market cap is $21.65 million. Biopharmx Corp has a 1-year low of $0.19 and a 1-year high of $1.22. The stock’s 50 day moving average price is $0.40 and its 200 day moving average price is $0.51.
Biopharmx Corp (NASDAQ:BPMX) last released its quarterly earnings results on Tuesday, June 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.07). The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.03 million. Biopharmx Corp had a negative return on equity of 1,847.04% and a negative net margin of 28,405.26%. Equities research analysts forecast that Biopharmx Corp will post ($0.31) earnings per share for the current year.
Several research firms have recently issued reports on BPMX. Roth Capital set a $3.00 price target on Biopharmx Corp and gave the stock a “buy” rating in a research note on Saturday, June 3rd. HC Wainwright set a $3.00 price target on Biopharmx Corp and gave the stock a “buy” rating in a research note on Thursday, June 15th. Finally, Maxim Group reiterated a “buy” rating and set a $3.00 price target on shares of Biopharmx Corp in a research note on Friday, June 2nd.
In related news, major shareholder Franklin Resources Inc bought 250,000 shares of the stock in a transaction that occurred on Tuesday, August 1st. The shares were acquired at an average price of $0.34 per share, with a total value of $85,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Biopharmx Corp Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.